This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
21 Dec 2011

Oncothyreon Files Investigational New Drug Application for ONT-10

Upon completion of the FDA's review of the IND, Oncothyreon expects to initiate a Phase 1 trial of ONT-10.

Seattle-based biotechnology company Oncothyreon Inc. announced Tuesday the filing of an Investigational New Drug (IND) application with the U.S. FDA for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1.

 

Upon completion of the FDA's review of the IND, Oncothyreon expects to initiate a Phase 1 trial of ONT-10.

 

"We are pleased to announce the filing of this IND, which is a significant milestone for our therapeutic vaccine development program," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. "ONT-10 and its adjuvant component, PET-Lipid A, were internally discovered and developed and remain fully owned by Oncothyreon."

 

Related News